Bioniche Life Sciences Inc. announced that it will nominate Mr. Anthony Macci for election to the Bioniche board of directors. Mr. Macci has extensive experience in manufacturing and supply chain management relating to the pharmaceutical, biotechnology and life science industry (including in the animal health field) and is a strong addition to the six highly qualified nominees previously identified by the Concerned Shareholders in their press release of May 14, 2013.

Bioniche Life Sciences Inc. announced the filing of a second requisition calling for a special meeting of the shareholders of Bioniche. The purpose of the requisitioned meeting is to remove from office all of the current directors of Bioniche and to fill the vacancies created by electing as directors the six highly qualified nominees listed below and one additional nominee of similar qualification to be named by Mr. Wells as soon as practicable and sufficiently in advance of the meeting to enable shareholders to form a reasoned judgment concerning the election of such nominee. The six highly qualified and experienced nominees to replace the Bioniche board are: Mr. Wells, Mr. Gubitz, Mr. J. Spencer Lanthier, Mr. Serge Gouin, Dr. Rochelle K. Seide and Mr. Hugo Wahnish. Mr. Wells served as Chief Executive Officer of Biovail Corporation (Biovail) from May 2008 to September 2010. Since 2010, Mr. Gubitz has been an independent advisor to companies, private equity firms and senior executives in the pharmaceutical and health care sector. Mr. Gubitz served at Biovail from 2006-2010 in various senior capacities, most recently as Senior Vice President, Corporate Development and General Counsel. Mr. Lanthier, CM, FCA, LL.D, is a chartered accountant and has been a professional corporate director since 2000. Mr. Lanthier retired as a partner at KPMG Canada in 1999. From 2005-2013 Mr. Gouin was the Chairman of Quebecor Media Inc., and from 2011-2013 he was the Chairman of TVA Group Inc. Dr. Rochelle Seide, Ph.D., J.D., is a highly experienced senior life sciences and intellectual property attorney. Dr. Seide is currently a member of the Development and Advisory Board (Business Affairs and Intellectual Property) of Larasan Pharmaceutical Corporation (since 2013) and a life sciences and intellectual property consultant (since 2011). Mr. Wahnish served as Chief Commercial Officer at Merck Animal Health until the end of 2012.

Bioniche Life Sciences Inc. (TSX:BNC) hired Evercore Partners Inc. (NYSE:EVR) to assist the Board of Directors and management in the divestment of the Animal Health business. "Three large Animal Health companies have now expressed interest, in writing, in executing a purchase of the company's Animal Health business. Evercore's track record in successfully negotiating such transactions and its extensive network of contacts in the animal health industry make it an ideal firm to lead this exercise," said James Rae, Chairman of the Board of Directors of Bioniche Life Sciences Inc.